New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
10:32 EDTHZNP, IDTI, MGA, CTIC, HSHHigh option volume stocks: HSH MGA HZNP CTIC IDTI
News For HSH;MGA;HZNP;CTIC;IDTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
09:24 EDTMGAJohnson Controls Magna could be hurt by Toyota consolidation, says Wells Fargo
Wells Fargo beleives that Johnson Controls (JCI) and Magna (MGA) could be hurt in the intermediate term by Toyota's (TM) decision to merge the seating manufacturing operations of four of its affiliates. Wells thinks Toyota's move should make bidding for seating deals more competitive. It keeps Market Perform ratings on Johnson Controls and Magna.
December 18, 2014
06:34 EDTIDTIIntegrated Device shipped over 100M PCIe buffers, 3M low-power PCIe Gen3 buffers
Integrated Device announced that it has shipped over 100M PCIe buffers and over 3M low-power PCIe Gen3 buffers, cementing its role as a key enabling and validation partner of leading x86 and ARM-based CPU and chipset suppliers. IDT’s low-power PCIe Gen3 buffers apply IDT’s long-proven, patented, low-power HCSL technology to address three major customer concerns. The buffers reduce operating costs, save board space, and support longer PCIe connection topologies.
December 9, 2014
05:56 EDTCTICCTI BioPharma presents Pacritinib data at ASH meeting
Subscribe for More Information
December 7, 2014
14:25 EDTCTICCTI BioPharma announces analysis of kinase inhibition by pacritinib
CTI BioPharma announced that an analysis of kinase inhibition by pacritinib, a next generation oral multikinase inhibitor in Phase 3 clinical development, demonstrated a unique kinome profile among agents in development for myelofibrosis and suggests potential therapeutic benefit across a spectrum of blood-related cancers. Researchers presented the findings from this analysis at the 56th American Society of Hematology Annual Meeting and Exposition held December 6-9 in San Francisco, CA."The kinome profile of pacritinib shown in this analysis highlights how pacritinib is different from other JAK inhibitors that are currently on the market and in development for myelofibrosis," said Srdan Verstovsek, M.D., Ph.D., Director, Clinical Research Center for MPNs at The University of Texas MD Anderson Cancer Center and principal investigator for the Phase 3 PERSIST-2 trial of pacritinib. "One of the findings observed in clinical trials to date is the lack of myelosuppression seen with other treatments. Pacritinib's potent inhibition of FLT3, c-fms, IRAK1 and c-kit, all critical targets in hematologic malignancies, highlights its potential therapeutic utility in other indications, such as AML, MDS, CMML and CLL." The in vitro profiling of pacritinib across a panel of kinases showed the inhibition of all members of the JAK/FLT pathways, with the exception of JAK1. The JAK/FLT pathways are frequently dysregulated in many types of cancers. Additionally, pacritinib was found to inhibit the kinases c-fms and IRAK1. Disruption in the c-fms and IRAK1 pathways have been indicated to be involved in acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia and chronic lymphocytic leukemia. CTI believes the clinical efficacy and reduced myelosuppression seen in Phase 2 trials of pacritinib in patients with myelofibrosis is also likely attributable to this unique kinase inhibition profile. "These data not only demonstrate the unique attributes of pacritinib compared to other marketed agents or agents in development for the treatment of myelofibrosis, many of which have activity against JAK1, but also show the potential for broader use in other blood-related cancers," said Jack Singer, M.D., Executive Vice President, Global Medical and Translational Medicine at CTI and lead author of the analysis. "We are excited to pursue additional indications, such as AML, MDS, CMML and CLL, all of which are currently being evaluated in Phase 2 clinical trials, so we can potentially offer these patients an effective and less toxic treatment option."
14:10 EDTCTICAmerican Society of Hematology to hold a meeting
Subscribe for More Information
14:08 EDTCTICCTI BioPharma to hold a cocktail reception
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use